The 2020 CSCO treatment guidelines for NSCLC (7) recommend bevacizumab combined with chemotherapy for LUAD with an EGFR mutation, which can also provide therapeutic benefits for ccRCC. This evidence concerns the gene EGFR and nonpapillary renal cell carcinoma.